An observational study in Metastatic Urothelial Cancer, sponsored by Astellas Pharma Singapore Pte. Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-24.
Sponsored by Astellas Pharma Singapore Pte. Ltd. · Observational
Cancer in the bladder lining (urothelial cancer) can be treated in many ways. One way is to directly attack cancer cells. Enfortumab vedotin is a treatment that can do this. Another way is to help the body's immune system find and attack cancer cells. Avelumab is a treatment that can do this. Both treatments were recently approved in some countries.
Doctors have standard clinical practice guidelines to help them treat people with cancer. This study is about collecting information on how adults with urothelial cancer are treated in standard clinical practice. The people in this study will have locally advanced or metastatic urothelial cancer. Locally advanced means the cancer has spread to tissue close by.
Metastatic means the cancer has spread to other parts of the body.
The goal of this study is to learn how people with urothelial cancer receive medical care in clinics in South Korea and Saudi Arabia. The main goals are to learn more about the people receiving treatments, and the treatments they receive.
This study is about collecting information only. The individual's doctor decides on treatment, not the study sponsor (Astellas).
Information will be collected from the people's medical records. This will include 12 months before treatment starts, and during treatment. Also, doctors will answer questions in interviews and surveys about how they care for people with urothelial cancer.
Astellas Pharma Singapore Pte. Ltd. is the lead sponsor of 9 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
LA/mUC patients being treated by medical oncologists and urologists in Saudi Arabia and South Korea. Patients will be sampled within a routine care setting in that they are consulting a physician through a pre-planned appointment.
Physician sample:
Patient sample:
Exclusion Criteria:
LA/mUC patient record-based survey of medical oncologists and urologists in Saudi Arabia and South Korea.
Other: No intervention
No investigational drug will be administered to participants in this study.
Demographics associated with LA/mUC patients at various stages of treatment pathway
Demographics of interest will be recorded.
Time frame: Day 1
Clinical characteristics associated with LA/mUC patients at various stages of treatment pathway
Clinical characteristics of interest will be recorded.
Time frame: Day 1
Therapies received at data collection and any therapies previously received for LA/mUC.
Details of current and previous therapies received for LA/mUC will be recorded.
Time frame: Day 1
Healthcare resource utilization of 1L and 2L+ LA/mUC patients
LA/mUC Healthcare resources will be recorded.
Time frame: Day 1
Current molecular/genetic testing patterns in LA/mUC patients
Tumor biomarker, genetic tests results and PD1/PD-L1 expression status will be recorded.
Time frame: Day 1
Current diagnostic tools in LA/mUC patients
Tests and assessments used to diagnosis patient's LA/mUC will be recorded.
Time frame: Day 1
Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
No publications or documents are linked to this record.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Astellas Pharma Singapore Pte. Ltd.